Electronic Journal of General Medicine

• American Diabetes Association (ADA). Diagnosis and classification 0f Diabetes Mellitus. Diabetes care 2005; 28: S37- S42.
• Ostergard T, Ek J, Hamid Y, Saltin B, et al. Influence of PPAR-γ2, Pro 12Ala and ACE I/D polymorphisms on insulin sensitivity and training effects in healthy offspring of type 2 diabetic subjects. Horm Metab Res 2005;37: 99-105.
• Ghoussaini M, Meyre D, Lobbens S, Charpentier G, et al. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med Genet 2005;6:1-8.
• Powers AC. Diabetes Mellitus. Harrison’s principles of internal medicine 15th edition, chapter XIII Endocrinology and Metabolism 2001:2109-24.
• Florian B, Yasunori T, Evren C, et al. Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology 2006;26:28-40.
• Forman BM, Chen J and Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for PPAR [alpha] and PPAR[delta]. Proc Natl Acad Sci 1997;94:4312-7.
• Béatrice D and Walter W. Peroxisome ProliferatorActivated Receptors: Nuclear Control of Metabolism. The Endocrine Society 1999; 20(5): 649-688.
• Guan HP, Yong L, Jensen MV, Newgard CB, et al. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nature Medicine 2002;8:1122-8.
• Marx N, Froehlich J, Siam L, Ittner J, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003;23: 283–8.
• Evans RM, Barish GD and Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355–61.
• Greene ME, Blumberg B, McBride OW, Yi HF, et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 1995;4:281-99.
• Beamer BA, Negri C, Yen CJ, Gavrilova O, et al. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-[gamma] (hPPAR[gamma]) gene. Biochem Biophys Res Commun 1997;233:756-9.
• Chu R, Madison LD, Lin Y, Kopp P, et al. Thyroid hormone (T3) inhibits ciprofibrate-induced transcription of gene encoding [beta]-oxidation enzymes: Cross-talk between peroxisome proliferator and T3 signaling pathways. Proc Natl Acad Sci USA 1995;92:11593-7.
• Moller DE and Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56:45-62.
• Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptorgamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000;268:178-82.
• Flegal KM, Carroll MD, Ogden CL and Johnson CL. Prevalence and trends in obesity among US adults. JAMA 2002;288:1723–7.
• Katsuki A, Sumida Y, Esteban C, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow up of patients with type 2 diabetes mellitus. Diabetes Care 2001;24:362-5.
• Ek J, Urhammer SA, Sorensen TI, Andersen T, et al. Homozygosity of the Pro 12 Ala variant of the peroxisome proliferator-activated receptor-γ2 (PPAR γ2): Divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999;42: 92-5.
• Kim SY, Kim HI, Park SK, Im SS, Li T, et al. Liver glucokinase can be activated by peroxisome proliferatoractivated receptor-gamma. Diabetes 2004;53(Suppl 1): 66–70.
• Radha V, Vimaleswaran KS, Babu HN, et al. Role of Genetic Polymorphism Peroxisome Proliferator–Activated Receptor gamma-2 Pro12Ala on Ethnic Susceptibility to Diabetes in South-Asian and Caucasian Subjects. Diabetes Care 2006;29:1046-51.
• Doney AS, Fischer B, Cecil JE, et al. Association of the pro 12 Ala and C1431T variants of PPARG and their haplotypes with susceptibility to type 2 diabetes. Diabetologia 2004;47:555-8.
• Memisoglu A, Hu FB, Hankinson SE, et al. Prospective Study of the Association Between the Proline to Alanine Codon 12 Polymorphism in the PPAR[gamma] Gene and Type 2 Diabetes. Diabetes Care 2003;26:2915-7.
• Caramori ML, Canani LH, Costa LA and Gross JL. The human peroxisome proliferator- activated receptor γ2 Pro 12 Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003;52:3010-3.
• Mancini FP, Sabatino L, Tufano A, et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes. Brief genetics report. Diabetes 1999;48:1466-8.
• Ringel J, Engeli S, Distler A, Sharma AM. Pro12 Ala minsense mutation of the peroxisone proliferator activated receptor γ and diabetes mellitus. Biochem Biophys Res Commun 1999;254:450-3.
• Soriquer F, Morcillo S, Cardona F, et al. Pro 12 Ala polymorphism of PPAR gamma 2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J Nutr 2006;136:2325-30.
• Tavares V, Hirata RD, Rodrigues AC, et al. Association between Pro 12 Ala polymorphism of PPAR-γ2 gene and insulin sensitivity in Brazilian patients with type 2 diabetes mellitus. Blackwell Publishing. Diabetes, Obesity and Metabolism 2004;7:605-611.
• Stumvoll M and Haring H. The Peroxisome ProliferatorActivated Receptor-[gamma]2 Pro12Ala Polymorphism. American Diabetes Association, Inc 2002;51:2341-7.
• Dubois M, Pattou F, Kerr-Conte J, Gmyr V, et al. Expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) in normal human pancreatic islet cells. Diabetologia 2000;43:1165-9.
• McGarry JD. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51:7–18.
• Ze-Kuan, Neng-Guin MA, Chang-Yan, et al. Role of Peroxisome Proliferator-Activated Receptor Gamma in Glucose-induced Insulin Secretion. Acta Biochimica et Biophysica Sinica 2006;38:1–7.
• Stevan N, Fritsche A, Haring H and Stumvoll M. Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of peroxisome-proliferator-activated receptor-[gamma]2 gene. Diabetes 2001;50:1143-8.
• Scaglioni S, Verduci E, Salvioni M, et al. PPAR gamma 2 Pro 12 Ala variant, insulin resistance and plasma long chain polyunsaturated fatty acids in childhood obesity. Pediatr Res 2006;60:485-9.
• Kao L, Coresh J, Shuldiner AR, et al. Pro 12 Ala polymorphism of PPAR gamma 2 gene is associated with lower serum insulin in non obese African- Americans. Diabetes 2003;52:1568-72.
• Bouassida KZ, Chouchane L, Jellouli K, et al. The peroxisome proliferator activated receptorγ2 (PPARγ2) Pro12Ala variant: Lack of association with type 2 diabetes in obese and non obese Tunisian patients. Masson 2005;31:119-23.
• Altshuler D, Hirschhorn JN and Klannemark M. The common PPAR-γ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76- 80.
• Lie HH, Chen MH, Yang WS, et al. Peroxisomes proliferators activated receptors gamma 2 Pro12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism 2000;49:1267-70.
• Douglas JA, Erdos MR, Watanabe RM, et al. The peroxisome proliferator-activated receptor-γ2 Pro12Ala variant. Association with type 2 diabetes and traits differences. Diabetes 2001;50:886-90.

Vancouver

Sokkar S, El-Sharnouby JA, Helmy A, El-Bendary A, Ahmad LS, Okasha K. Role of Peroxisome Proliferator-Activated Receptor gamma 2 (PPAR-γ2) Gene Polymorphism in Type 2 Diabetes Mellitus. EUR J GEN MED. 2009;6(2):78-86. https://doi.org/10.29333/ejgm/82645

APA

Sokkar, S., El-Sharnouby, J. A., Helmy, A., El-Bendary, A., Ahmad, L. S., & Okasha, K. (2009). Role of Peroxisome Proliferator-Activated Receptor gamma 2 (PPAR-γ2) Gene Polymorphism in Type 2 Diabetes Mellitus. European Journal of General Medicine, 6(2), 78-86. https://doi.org/10.29333/ejgm/82645

AMA

Sokkar S, El-Sharnouby JA, Helmy A, El-Bendary A, Ahmad LS, Okasha K. Role of Peroxisome Proliferator-Activated Receptor gamma 2 (PPAR-γ2) Gene Polymorphism in Type 2 Diabetes Mellitus. EUR J GEN MED. 2009;6(2), 78-86. https://doi.org/10.29333/ejgm/82645

Chicago

Sokkar, Salwa, Jehan A. El-Sharnouby, Amal Helmy, Amal El-Bendary, Laila Sayed Ahmad, and Kamal Okasha. "Role of Peroxisome Proliferator-Activated Receptor gamma 2 (PPAR-γ2) Gene Polymorphism in Type 2 Diabetes Mellitus". European Journal of General Medicine 2009 6 no. 2 (2009): 78-86. https://doi.org/10.29333/ejgm/82645

Harvard

Sokkar, S., El-Sharnouby, J. A., Helmy, A., El-Bendary, A., Ahmad, L. S., and Okasha, K. (2009). Role of Peroxisome Proliferator-Activated Receptor gamma 2 (PPAR-γ2) Gene Polymorphism in Type 2 Diabetes Mellitus. European Journal of General Medicine, 6(2), pp. 78-86. https://doi.org/10.29333/ejgm/82645

MLA

Sokkar, Salwa et al. "Role of Peroxisome Proliferator-Activated Receptor gamma 2 (PPAR-γ2) Gene Polymorphism in Type 2 Diabetes Mellitus". European Journal of General Medicine, vol. 6, no. 2, 2009, pp. 78-86. https://doi.org/10.29333/ejgm/82645